Table of contents
- Trial overview
- Phase 2 study in FSHD1
- Phase 3 study in pediatric NMOSD
- Outcomes and measures used in the trials
- What participants should know from the trial data
Trial overview
The trial data include two authorised interventional studies of Satralizumab.[1][2] One study is in type 1 facioscapulohumeral muscular dystrophy (FSHD1), and the other is in neuromyelitis optica spectrum disorder (NMOSD) in children with AQP4 antibodies.[1][2] Both studies are designed to learn more about how well Satralizumab works and how safe it is in the target group, while the pediatric study also looks at pharmacokinetics.[1][2]
Phase 2 study in FSHD1
The first study is a randomized trial, which means participants are assigned by chance to a treatment group, and it is double blind, which means the participants and study team do not know who gets which treatment during the blinded period.[1] It is also placebo-controlled, so Satralizumab is compared with a placebo that looks the same but does not contain the active ingredient.[1] This Phase 2 study is designed for people with FSHD1 and plans to enroll 46 participants.[1]
The main goal is to compare Satralizumab with placebo over 48 weeks of the double-blind period.[1] Researchers want to see whether Satralizumab changes whole body muscle MRI findings, the RICCI clinical severity scale, reachable work space, muscle strength, the FSHD-Composite Outcome Measure, and the FSHD-Rasch-built overall disability scale.[1] They also assess patient-reported and clinician-reported change scales, the number of falls, upper-limb and walking independence, inflammation markers, and safety outcomes.[1]
The safety part of this study looks at the type, frequency, severity, and seriousness of adverse events, which are unwanted medical events that happen during a study.[1] It also checks adverse events of special interest, study drug discontinuation because of an adverse event, and changes in laboratory tests, vital signs, and physical examination results.[1]
Phase 3 study in pediatric NMOSD
The second trial is a Phase 3 study in pediatric patients with AQP4 antibody-positive NMOSD.[2] It plans to enroll 21 children aged 2 to 11 years.[2] This study is focused on pharmacokinetics, efficacy, safety, tolerability, and pharmacodynamics, which means how the drug behaves in the body and what effects it may have.[2]
The main outcomes are serum concentration measurements at specific trough timepoints and population and individual estimates of pharmacokinetic parameters using a population-PK model.[2] In simple words, the study measures how much Satralizumab is in the blood at certain times and uses that information to understand drug exposure over 24 weeks.[2]
Outcomes and measures used in the trials
The FSHD1 study uses many outcome measures to capture different parts of the disease.[1] These include imaging of muscles with MRI, clinical severity scoring, movement range, strength testing, disability scales, and the number of falls.[1] It also looks at inflammation-related molecular biomarkers such as IFN-γ, IL-1β, IL-6, TNF-α, VEGF, IL1-RA, IL-6-R, sICAM-1, sVCAM-1, and SAA.[1]
The pediatric NMOSD study has a narrower main focus on blood levels of Satralizumab and pharmacokinetic modeling.[2] This is important because younger children may handle medicines differently from older children or adults.[2]
What participants should know from the trial data
From the trial records, the FSHD1 study is a comparison between Satralizumab and placebo, while the pediatric NMOSD study gives Satralizumab to children and measures how the body processes it.[1][2] The studies are not in the same disease, age group, or phase, so they answer different research questions.[1][2] Together, they show that researchers are testing Satralizumab in both a rare muscle disease and a rare nervous system disease.[1][2]
